<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Spurious</title>
	<atom:link href="http://www.tapanray.in/tag/spurious/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>When Pills Betray Trust</title>
		<link>http://www.tapanray.in/when-pills-betray-trust/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=when-pills-betray-trust</link>
		<comments>http://www.tapanray.in/when-pills-betray-trust/#comments</comments>
		<pubDate>Sun, 02 Nov 2025 07:25:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[betray]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[lies]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceuical]]></category>
		<category><![CDATA[pills]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trust]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10993</guid>
		<description><![CDATA[Why India’s Drug Quality Crisis Demands a Mindset Reset? A Familiar Headline, a Fading Sense of Shock: It happened again. According to The Economic Times (October 24, 2025), 112 drug samples failed quality tests in September — one even found spurious. If that &#8230; <a href="http://www.tapanray.in/when-pills-betray-trust/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/when-pills-betray-trust/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Unseen Terror: Fake Drugs Claim More Lives Than Terrorism in India</title>
		<link>http://www.tapanray.in/the-unseen-terror-fake-drugs-claim-more-lives-than-terrorism-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-unseen-terror-fake-drugs-claim-more-lives-than-terrorism-in-india</link>
		<comments>http://www.tapanray.in/the-unseen-terror-fake-drugs-claim-more-lives-than-terrorism-in-india/#comments</comments>
		<pubDate>Thu, 15 May 2025 07:43:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[death]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Terror]]></category>
		<category><![CDATA[terrorism]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10896</guid>
		<description><![CDATA[In May 2025, the Union Health Ministry acknowledged in a response to the Lok Sabha that over 7,500 drug samples failed quality tests across India in the previous year, with spurious drugs reported from nearly every major state. The admission, &#8230; <a href="http://www.tapanray.in/the-unseen-terror-fake-drugs-claim-more-lives-than-terrorism-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-unseen-terror-fake-drugs-claim-more-lives-than-terrorism-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Blockchain: A Game Changer For Safe Medicines</title>
		<link>http://www.tapanray.in/blockchain-a-game-changer-for-safe-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=blockchain-a-game-changer-for-safe-medicines</link>
		<comments>http://www.tapanray.in/blockchain-a-game-changer-for-safe-medicines/#comments</comments>
		<pubDate>Mon, 09 Jul 2018 00:00:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[anti-counterfeit]]></category>
		<category><![CDATA[Blockchain]]></category>
		<category><![CDATA[Changer]]></category>
		<category><![CDATA[combating]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[economic]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[Genentech]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[measures]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[menace]]></category>
		<category><![CDATA[Niti]]></category>
		<category><![CDATA[Niti Aayog]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9049</guid>
		<description><![CDATA[‘Your medicine box may have fake drugs’ was the March 18, 2018 headline of a popular pan Indian news daily. Just the year before, the 2017 report of the World Health Organization (WHO), also flagged that around 10.5 percent of all medicines in &#8230; <a href="http://www.tapanray.in/blockchain-a-game-changer-for-safe-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/blockchain-a-game-changer-for-safe-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Fake Drugs Kill More People Each Year Than Terrorism In The Last 40 years&#8217;</title>
		<link>http://www.tapanray.in/fake-drugs-kill-more-people-each-year-than-terrorism-in-the-last-40-years/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fake-drugs-kill-more-people-each-year-than-terrorism-in-the-last-40-years</link>
		<comments>http://www.tapanray.in/fake-drugs-kill-more-people-each-year-than-terrorism-in-the-last-40-years/#comments</comments>
		<pubDate>Mon, 29 Jun 2015 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2009]]></category>
		<category><![CDATA[Anil]]></category>
		<category><![CDATA[ASSOCHAM]]></category>
		<category><![CDATA[CBI]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Director]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[FICCI]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[INTERPOL]]></category>
		<category><![CDATA[kill]]></category>
		<category><![CDATA[Ostrich Syndrome]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Sinha]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[substandard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[terrorism]]></category>
		<category><![CDATA[Wolf in sheep's clothing]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6767</guid>
		<description><![CDATA[In this article, I shall deliberate on ‘fake medicines’ that we may at times land up into buying, without any inkling that instead of curing or managing the ailments, these products can push us into serious health hazards, quite contrary &#8230; <a href="http://www.tapanray.in/fake-drugs-kill-more-people-each-year-than-terrorism-in-the-last-40-years/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/fake-drugs-kill-more-people-each-year-than-terrorism-in-the-last-40-years/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Ten Step Strategy Prescribed</title>
		<link>http://www.tapanray.in/a-ten-step-strategy-prescribed/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-ten-step-strategy-prescribed</link>
		<comments>http://www.tapanray.in/a-ten-step-strategy-prescribed/#comments</comments>
		<pubDate>Mon, 24 Dec 2012 00:00:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[prescribed]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[ten]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1101</guid>
		<description><![CDATA[In India, there are various hurdles to address the healthcare issues in a comprehensive way. Though, these do not seem to be insurmountable, the country needs a clear time-bound grand strategy to squarely address this vexing concern, which also has its &#8230; <a href="http://www.tapanray.in/a-ten-step-strategy-prescribed/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-ten-step-strategy-prescribed/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Hysteria on Corporate Lobbying in India</title>
		<link>http://www.tapanray.in/hysteria-on-corporate-lobbying-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=hysteria-on-corporate-lobbying-in-india</link>
		<comments>http://www.tapanray.in/hysteria-on-corporate-lobbying-in-india/#comments</comments>
		<pubDate>Mon, 17 Dec 2012 00:00:42 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[hysteria]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[lobbying]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1104</guid>
		<description><![CDATA[The &#8216;hysteria&#8217; on &#8216;Corporate Lobbying&#8217; influencing the key policy decisions of India, reverberated in the corridors of power of the Indian Parliament last week with consequent media attraction and triggering a raging public debate. On Monday, December 10, 2012 the Upper &#8230; <a href="http://www.tapanray.in/hysteria-on-corporate-lobbying-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/hysteria-on-corporate-lobbying-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A NEW Study on Ballooning Pharma R&amp;D Cost: Exploring a Sustainable Model for Greater Patients’ Access</title>
		<link>http://www.tapanray.in/a-new-study-on-ballooning-pharma-rd-cost-exploring-a-sustainable-model-for-greater-patients-access/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-new-study-on-ballooning-pharma-rd-cost-exploring-a-sustainable-model-for-greater-patients-access</link>
		<comments>http://www.tapanray.in/a-new-study-on-ballooning-pharma-rd-cost-exploring-a-sustainable-model-for-greater-patients-access/#comments</comments>
		<pubDate>Mon, 10 Dec 2012 00:00:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1057</guid>
		<description><![CDATA[The high-decibel debate on increasing prices for patented drugs affecting patients’ access to innovative medicines gets a new fuel. A brand new study dated December 2012 carried out by the Office of Health Economics (OHE), UK, which was partly supported by a &#8230; <a href="http://www.tapanray.in/a-new-study-on-ballooning-pharma-rd-cost-exploring-a-sustainable-model-for-greater-patients-access/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-new-study-on-ballooning-pharma-rd-cost-exploring-a-sustainable-model-for-greater-patients-access/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Revocation and Denial of Patents on Patentability Ground in India: The Fallout and the Road Ahead</title>
		<link>http://www.tapanray.in/revocation-and-denial-of-patents-on-patentability-ground-in-india-the-fallout-and-the-road-ahead/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=revocation-and-denial-of-patents-on-patentability-ground-in-india-the-fallout-and-the-road-ahead</link>
		<comments>http://www.tapanray.in/revocation-and-denial-of-patents-on-patentability-ground-in-india-the-fallout-and-the-road-ahead/#comments</comments>
		<pubDate>Mon, 03 Dec 2012 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[denial]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[fallout]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[ground]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[revocation]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1060</guid>
		<description><![CDATA[On November 26, 2012, the Intellectual Property Appellate Board (IPAB) reportedly denied patent protection for AstraZeneca’s anti-cancer drug Gefitinib on the ground that the molecule lacked invention. The report also states that AstraZeneca suffered its first setback on Gefitinib in June 2006, &#8230; <a href="http://www.tapanray.in/revocation-and-denial-of-patents-on-patentability-ground-in-india-the-fallout-and-the-road-ahead/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/revocation-and-denial-of-patents-on-patentability-ground-in-india-the-fallout-and-the-road-ahead/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Conundrum of Stringent IPR Regime in India: Responsible Pricing still remains ‘The Final Frontier’</title>
		<link>http://www.tapanray.in/the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier</link>
		<comments>http://www.tapanray.in/the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier/#comments</comments>
		<pubDate>Mon, 26 Nov 2012 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[final]]></category>
		<category><![CDATA[frontier]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[regime]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[responsible]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[stringent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1063</guid>
		<description><![CDATA[In his management classic named, ‘The Practice of management’, published in 1954, the universal management guru Peter Drucker postulated that any successful business is driven by only the following two fundamental functions: Marketing Innovation …and all the rests are costs. &#8230; <a href="http://www.tapanray.in/the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-conundrum-of-stringent-ipr-regime-in-india-responsible-pricing-still-remains-the-final-frontier/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Old is Always Not Gold&#8217;: The Saga of Uncertainty on the New Drug Policy Continues</title>
		<link>http://www.tapanray.in/old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues</link>
		<comments>http://www.tapanray.in/old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues/#comments</comments>
		<pubDate>Mon, 19 Nov 2012 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Always]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Continues]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[gold]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[uncertainty]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1066</guid>
		<description><![CDATA[Along with the initiation of globalization process of India in 1991, many significant reform oriented steps are being taken by the Government for the pharmaceutical industry as its growth booster. In tandem with gradual reduction in the span of price &#8230; <a href="http://www.tapanray.in/old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/old-is-always-not-gold-the-saga-of-uncertainty-on-the-new-drug-policy-continues/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
